| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Tudor Pop
Jenna Brashear
Rosalio Madrigal
| Share Statistics | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7,247.5 | $226.9 | 73% |
|
| Shares Out (Mil) | 84.9 | 53.4 | 59% |
|
| Institutional Ownership | 92.9% | 92.9% | 62% |
|
| Float (Mil) | 39.9 | 40.7 | 42% |
|
| Beta | 0.04 | 0.95 | 7% |
|
| Avg Daily Volume (000s) | 1,184 | 469 | 73% |
|
| Price Change (52-week) |
146.8% | 46.6% | 98% |
|
| Growth | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 18.8% | (10.1%) | 71% |
|
| EPS (5yr) | 18.0% | 15.8% | 65 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.3%) | (15.7%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | $0.390 | $1.910 | $2.155 | |
| Month Ago EPS | $0.288 | $1.158 | $1.618 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.288 | $1.158 | $1.618 | |
| Year/Year Chg | (30.4%) | 154.7% | 252.7% | |
| Financials | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $946 | $37 | 49% |
|
| Net Income (TTM) (Mil) | $110 | ($44) | 61% |
|
| EPS (TTM) | $1.422 | ($1.600) | 65% |
|
| Operating Cash Flow (TTM) (Mil) | $199 | ($33) | 59% |
|
| Net Cash Flow (TTM) (Mil) | ($93) | $2 | 15% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $4 | 23% |
|
| Enterprise Value (Q1) (Mil) | $6,918 | $174 | 68% |
|
| Valuation | KNSA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.19 | 2.17 | 91% |
|
| P/E | 69.7 | 20.2 | 90% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 3.9 | 1.0 | 84% |
|
| Ratios | KNSA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 54.3% | 65.6% | 66% |
|
| Net Margin | 11.6% | (71.5%) | 66% |
|
| ROA | 12.9% | (47.1%) | 91% |
|
| ROE | 17.6% | (53.0%) | 76% |
|
| Liabilities to Assets | 27.8% | 29.6% | 19% |
|
| F-Score | 8 | 2 | 93% |
|
Kiniksa Pharmaceuticals International, plc did not pass any screens on 10/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
